Lannett, Novitium to offer generic levorphanol
Lannett has entered into an exclusive U.S. distribution agreement for levorphanol tablets with Novitium Pharma. The product is the generic of Sentynl Therapeutics’ levorphanol tartrate tablets 2 mg.
Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits. Other financial terms were not disclosed.
"We are pleased to establish a new strategic relationship with Novitium Pharma, a private company with a growing portfolio of commercial products," said Tim Crew, Lannett CEO. "Novitium received FDA approval earlier this month of its ANDA for levorphanol tablets 2 mg, a product currently with a small number of competitors. Levorphanol tablets 2 mg is a solid addition to our product offering."
Levorphanol tablets 2 mg had a market value of roughly $60.9 million, for the 12 months ended May 2020, according to IQVIA, although the company said actual generic market values are expected to be lower.